BioRestorative Therapies (BRTX) Liabilities and Shareholders Equity (2010 - 2025)

BioRestorative Therapies (BRTX) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $4.1 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 66.78% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.6 million (down 53.11% YoY) and the FY2025 annual result came in at $4.1 million, down 66.78% from the prior year.
• Liabilities and Shareholders Equity slipped to $4.1 million in Q4 2025, from $5.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $22.5 million in Q4 2021 to a low of $2.2 million in Q3 2021.
• A 5-year average of $12.5 million and a median of $13.6 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 723.9% — and 2025, when it tumbled 66.78%.
• Tracing BRTX's Liabilities and Shareholders Equity over 5 years: stood at $22.5 million in 2021, then declined by 26.81% to $16.4 million in 2022, then retreated by 23.26% to $12.6 million in 2023, then fell by 2.63% to $12.3 million in 2024, then plunged by 66.78% to $4.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $4.1 million (Q4 2025), $5.6 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.